Armistice Capital, LLC Nektar Therapeutics Transaction History

Armistice Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.66 - $1.19 $7,920 - $14,280	12,000 Added 1.17%	1,036,000 $704,000
Q4 2024 Feb 14, 2025	BUY	$0.9 - $1.45 $21,600 - $34,800	24,000 Added 2.4%	1,024,000 $952,000
Q3 2024 Nov 14, 2024	BUY	$1.11 - $1.48 $182,040 - $242,720	164,000 Added 19.62%	1,000,000 $1.3 Million
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $752,400 - $1.53 Million	836,000 New	836,000 $1.04 Million

15.6M

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $10.6B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Armistice Capital, LLC with notifications on news.